Testing a new cancer medication for children and young adults

Plain-English translation of NCT06395103 on ClinicalTrials.gov ↗ · Source last updated July 2026 · Translation generated August 2026 · How we translate trials

Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.

What is this trial?

This trial is testing a new cancer medication called in children and young adults who have certain types of blood cancer (like leukemia or lymphoma) or solid tumors (like neuroblastoma or Ewing sarcoma). The medication is given by IV infusion every 3 weeks in gradually increasing doses. Researchers want to understand if this treatment is safe and how well it works.

Many children and young adults with these cancers don't respond well to standard treatments, or their cancer comes back after treatment. This medication is being developed as a new option that might help patients whose cancers have not responded to previous therapies.

Do you qualify?

You likely qualify if…

you have been diagnosed with one of the specific cancers being studied: B-cell acute lymphoblastic leukemia, diffuse large B-cell lymphoma, Burkitt lymphoma, neuroblastoma, or Ewing sarcoma
your cancer has returned or stopped responding to previous treatment
you are between infancy and early adulthood (the exact age range depends on the cancer type)
you have recovered from any side effects of previous cancer treatments
you are willing to receive IV infusions every 3 weeks and attend regular study visits

You likely don't qualify if…

you have received an organ transplant
you have ongoing heart disease or liver cirrhosis
you have nerve damage (peripheral neuropathy) or Charcot-Marie-Tooth disease
you have or had a graft-versus-host disease or are being treated to prevent it
you have HIV, Hepatitis B, or active Hepatitis C

What participation looks like

You would receive the new medication as an IV infusion on the first day of each 3-week treatment cycle. The dose will start low and gradually increase over time as researchers monitor how your body responds. You will need to attend regular visits for blood tests, imaging scans, and check-ups to see how the treatment is working and watch for any side effects. The study lasts as long as the treatment continues to help your cancer and you tolerate it well.

AI-generated summary from trial data · Aug 5, 2026 · Not medical advice

Trial locations(71 sites)

United States

Children's Hospital Los Angeles ( Site 1006), Los Angeles, California

Children's Hospital Colorado-Center for Cancer and Blood Disorders ( Site 1016), Aurora, Colorado

Yale New Haven Hospital ( Site 1012), New Haven, Connecticut

Johns Hopkins All Children's Hospital ( Site 1025), St. Petersburg, Florida

University of Iowa-Holden Comprehensive Cancer Center ( Site 1017), Iowa City, Iowa